NCT05498064View on ClinicalTrials.gov

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

RecruitingOBSERVATIONAL
Enrollment

490

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 1, 2028

Conditions
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Interventions
DRUG

Ensartinib

Ensartinib 225 mg administered once daily orally

Trial Locations (1)

100730

RECRUITING

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER